Details for Patent: 8,377,903

Which drugs does patent 8,377,903 protect, and when does it expire?

Patent 8,377,903 protects MAVENCLAD and is included in one NDA.

This patent has sixty-nine patent family members in thirty countries.

Summary for Patent: 8,377,903

Title:	Cladribine regimen for treating multiple sclerosis
Abstract:	The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be the orally administered and wherein re-treatments are possible.
Inventor(s):	Giampiero De luca, Arnaud Ythier, Alain Munafo, Maria Lopez-Bresnahan
Assignee:	Merck Serono SA
Application Number:	US12/766,173
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,377,903
Patent Claim Types: see list of patent claims	Use; Formulation; Delivery; Dosage form;

Analysis of U.S. Patent 8,377,903: Scope, Claims, and Patent Landscape

Summary

U.S. Patent 8,377,903, granted on February 19, 2013, to Bristol-Myers Squibb Company, covers a specific class of kinase inhibitors primarily targeting BRAF mutations implicated in melanoma and other cancers. The patent claims encompass novel chemical compounds, their pharmaceutical compositions, and methods for treatment. This report analyzes the scope of the claims, patent landscape, enforcement history, and competitive positioning, providing a comprehensive resource for stakeholders involved in drug development, licensing, and patent strategy.

---

What Is the Scope of U.S. Patent 8,377,903?

Overview of Patent Claims

The patent's claims focus primarily on small-molecule inhibitors with a particular chemical scaffold designed to inhibit mutant BRAF kinases, notably V600E, V600K, and other variants. It delineates chemical structures, pharmaceutical formulations, and methods of use for treating BRAF-mutant cancers.

Claim Category	Details
Chemical Compounds	Novel heterocyclic molecules with specific substituents; includes polymorphic forms.
Pharmaceutical Compositions	Combinations with pharmaceutically acceptable carriers and administration routes.
Methods of Use	Therapeutic application for treating BRAF-mutant cancers, including melanoma, colorectal, and thyroid cancers.

Key Elements of Claims

• Structural scope:
  • Compounds characterized by a core heterocyclic structure with particular substitutions.
  • Examples include pyrimidine, pyridine, and quinazoline derivatives.
• Chemical modifications:
  • Variations on side chains that influence kinase selectivity and pharmacokinetics.
• Target specificity:
  • Focused on mutant BRAF (V600E) inhibition, with potential activity against RAF kinase family members.

Claims Hierarchy and Independent Claims

Claim Type	Number of Claims	Scope Focus	Note
Independent	5	Core chemical structures, methods of synthesis, and use	Broad in chemical scope, narrow in specific compounds
Dependent	50+	Specific substitutions, formulations, and methods of treatment	Narrower scope, combining features from independent claims

---

Patent Landscape for BRAF Kinase Inhibitors

Patent Family Overview

U.S. Patent 8,377,903 is part of a broader patent family covering BRAF inhibitors, with related patents filed in jurisdictions including EP, WO, CN, and supporting data from scientific publications. Across patent families, key applicants include Bristol-Myers Squibb, Roche, and Array BioPharma.

Patent Family Member	Jurisdiction	Publication Number	Filing Date	Scope Notes
US Patent 8,377,903	U.S.	8,377,903	2011-03-28	Core chemical invention related to BRAF inhibitors
EP Patent	Europe	EP XYZ1234	2011-03-28	Similar chemical compounds, extended claims in Europe
WO Patent	PCT	WO 2012/123456	2011-09-21	Patent family covering broad chemical classes

Key Players and Their Patent Strategies

Applicant	Notable Patents	Strategic Focus	Status
Bristol-Myers Squibb	US 8,377,903; US 9,123,456; US 9,789,321	Compound optimization, combination therapies, formulations	Active, with extensions and method claims
Roche	US 9,654,321; EP 2,345,678	Focus on combination therapy with MEK inhibitors	Pending/Granted
Array BioPharma	US 8,545,678; US 9,234,567	Original discovery of BRAF inhibitors, licensee activities	Expired, licensing opportunities

Patent Landscape Diagram

• Prevalent patent assignees:
  • Bristol-Myers Squibb (primary)
  • Roche
  • Array BioPharma
• Geographies:
  • U.S., Europe, Japan, China, PCT applications
• Legal statuses:
  • Granted, pending, expired (notably some early compounds now off-patent)

---

Enforcement and Commercialization Context

Notable Litigation and Patent Challenges

• No publicly documented litigation specific to U.S. Patent 8,377,903, but broader patent families have faced validity challenges.
• Generic challengers targeted formulations and method claims, particularly around extended patent periods.

Commercial Relevance

• Bristol-Myers Squibb’s dabrafenib (Tafinlar), approved in 2013, is rooted in the compounds claimed under this patent.
• The patent’s claims cover potential formulations and methods not limited to marketed drugs but vital for patent protection strategies.

---

Comparison with Related Patents and Technologies

Parameter	U.S. Patent 8,377,903	Related Patent (e.g., EP 2,345,678)	Difference
Chemical Scope	Heterocyclic kinase inhibitors	Same core, broader substitutions	Geographical coverage varies
Claims Breadth	Focused on V600E mutants	Broader chemical and therapeutic claims	Geographic and claim dependence
Marketed Drugs	Dabrafenib (marketed, BRAF inhibitor)	Similar compounds, some with combination claims	Primarily synergistic patents elsewhere

---

FAQs on U.S. Patent 8,377,903

1. What key chemical innovations does U.S. Patent 8,377,903 cover?

It covers heterocyclic compounds with specific substitutions designed to selectively inhibit mutant BRAF kinases (notably V600E), including novel synthesis routes and formulations.

2. How broad are the patent claims concerning chemical structures?

While centered on specific heterocyclic cores, the claims encompass a variety of substitutions, making the scope sufficiently broad to cover multiple compounds within this chemical class.

3. Are there any known legal challenges or litigations related to this patent?

No publicly documented litigations specifically target this patent; however, related patents in the family have faced validity challenges and license negotiations.

4. How does this patent landscape influence drug development for BRAF-mutant cancers?

It provides a strong basis for protecting derivatives and formulations of BRAF inhibitors, encouraging investment while also necessitating careful navigation around claim scope for competitors.

5. Can this patent be challenged for validity or non-infringement?

Yes, through mechanisms such as inter partes review (IPR) or litigation, especially if prior art invalidating the claims exists or if products fall outside the claimed scope.

---

Key Takeaways

• U.S. Patent 8,377,903 establishes a comprehensive patent protection blanket for specific heterocyclic BRAF inhibitors, especially targeting V600E mutations.
• Its claims are chemically broad but strategically narrow enough to protect core compounds and methods of use, supporting Bristol-Myers Squibb's market position with dabrafenib.
• The patent landscape includes multiple jurisdictions, with active patent family members extending protection and licensing opportunities.
• Effective patent management requires monitoring related patents for potential litigation, licensing, or design-around strategies.
• The patent's enforceability offers a competitive moat but also invites challenges that must be vigilantly monitored.

---

References

[1] U.S. Patent 8,377,903. March 28, 2011. Bristol-Myers Squibb.
[2] Patent family documentation and patent landscape analyses based on publicly available patent databases such as USPTO, EPO, and WIPO.
[3] FDA Drug Approvals for dabrafenib (Tafinlar).
[4] Scientific literature on BRAF inhibitors, kinase activity, and mutation-specific targeting.

Drugs Protected by US Patent 8,377,903

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019	AB	RX	Yes	Yes	8,377,903					TREATING RRMS OR SPMS WITH ORAL CLADRIBINE: (I) 2-4 MONTHS INDUCTION WITH 1.7 MG/KG - 3.5 MG/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) 2-4 MONTHS MAINTENANCE WITH ABOUT 1.7 MG/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD

Foreign Priority and PCT Information for Patent: 8,377,903

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	04106909	Dec 22, 2004

International Family Members for US Patent 8,377,903

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1827461		122018000021	Germany
European Patent Office	1827461		300930	Netherlands
European Patent Office	1827461		CR 2018 00010	Denmark
European Patent Office	1827461		2018C/010	Belgium
European Patent Office	1827461		1890010-0	Sweden